# Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma

> **NCT05954780** · — · ACTIVE_NOT_RECRUITING · sponsor: **iOMEDICO AG** · enrollment: 75 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Selinexor

## Key facts

- **NCT ID:** NCT05954780
- **Lead sponsor:** iOMEDICO AG
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-06-28
- **Primary completion:** 2026-10-30
- **Final completion:** 2026-10-30
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2026-01-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05954780

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05954780, "Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05954780. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*